




When to Use Amino Acid-Based Formula to Manage Cow Milk Allergy

Dr. Rosan Meyer & Dr. Carina Venter

April 30, 2019



Meet our speakers



Dr. Rosan Meyer

Pediatric Allergy Dietitian

Honorary Senior Lecturer, Imperial College, London UK
Visiting Professor KU Leuven, Belgium



Dr. Carina Venter

Assistant Professor of Pediatrics,
Section of Allergy and Immunology
Children's Hospital Colorado &
University of Colorado Denver School of Medicine

When to Use Amino Acid-Based Formula to Manage Cow Milk Allergy



Rosan Meyer (RD,PhD)

Paediatric Allergy Dietitian

April 2019

- PG Cert
- PG Diploma
- Master's degree
- Short courses



Disclosures

- Dr. Rosan Meyer:
 - Honorarium for today's webinar provided by Nutricia
 - Sponsored academic lectures: Mead Johnson & Nutricia
 - Advisory board affiliations: Mead Johnson
 - Research grants: Danone
- Dr. Carina Venter:
 - Honorarium for today's webinar provided by Nutricia
 - Sponsored academic lectures: Abbott, Mead Johnson & Nutricia
 - Teaching materials: Lil' Mixins, DBV technologies
 - Consultant: Nestle

*The opinions expressed by the speaker are independent of
Nutricia North America*

Learning Objectives

On completion, you should be able to:

1. Discuss factors that can influence choice of hypoallergenic formula.
2. Explain what guidelines advise on choice of hypoallergenic formula.
3. Name at least four practical indicators to use amino acid-based formula first line to manage cow milk allergy.


Cow Milk Allergy (CMA) is not uncommon

- Global prevalence:

- 1.9 - 4.9% of infants¹

- North American prevalence:

- ~2% of US infants^{2,3}
- Most common food allergen in infancy and early childhood²



Non-IgE-mediated allergies can involve CMA

- Eosinophilic esophagitis (EoE)
 - Cow milk = main EoE food trigger in US^{1,2}
- Food protein-induced enterocolitis syndrome (FPIES)
 - Cow milk = main FPIES food trigger in US³
- Atopic dermatitis / Eczema
 - Increasing evidence of CMA in delayed-onset disorders, including chronic eczema⁴



Support breastfeeding in infants with CMA

- All current guidelines support breast milk as first line choice for the dietary management of CMA^{1,3}
- Aim to follow WHO guidelines: 6 months exclusive breastfeeding; WHO suggests breastfeeding until 2 years of age
 - If maternal elimination is advised, needs to be supervised¹⁻³
 - Not always needed (e.g. FPIES²)
 - Consider vitamin and minerals (i.e. calcium, vitamin D)¹



When breast milk is not available....

INFANTS <1 yr




- ✓ Substitute formula:
 - Hypoallergenic OR
 - Soy (if tolerant) > 6 months of age^{1,2}

CHILDREN >1yr

- ✓ If ongoing allergy, continue with substitute formula until 2 years of age¹
- ✓ After 2 years of age, assess nutritional status to inform use of either substitute milk or formula

What factors can impact choice
of hypoallergenic formula?






Defining the term “Hypoallergenic”

Formula type: (protein source)	Amino acid- based (AAF)	Extensively hydrolyzed (eHF)
Protein Source	100% free amino acids	Cow milk
Peptide size, kilodaltons	N/A (free AAs ~0.12 ¹) 	Most <1.5 ² Up to 5% >3.5 ³ 
Allergenicity	<div style="display: flex; align-items: center; justify-content: space-between;"> Least  Most </div>	
Hypoallergenic? ²	✔ YES	✔ YES

“Hypoallergenic”

- North America: ≥90% of patients with CMA tolerate (with 95% CI)²
- Europe: Formulas labeled “HA” are partially hydrolyzed and should not be used for CMA⁴
- North America & Europe: Extensively hydrolyzed/amino acid-based formulas are recommended for CMA⁵

Only 2 formula types are hypoallergenic

Formula type: (protein source)	Amino acid- based (AAF)	Extensively hydrolyzed (eHF)	Partially hydrolyzed (pHF)	Regular (Intact protein)
Protein source	100% free amino acids	Cow milk	Cow milk	Cow milk
Peptide size, kilodaltons	N/A (free AAs ~0.12 ¹) 	Most <1.5 ² Up to 5% >3.5 ³ 	Dairy: Most <5 ³ and up to 18% >6 ³ 	Dairy: 14-67 ³ Soy: 20-225 ⁴ 
Allergenicity	<div style="display: flex; align-items: center; justify-content: center;"> Least  Most </div>			Most
Hypoallergenic? ²	<input checked="" type="checkbox"/> YES	<input checked="" type="checkbox"/> YES	<input checked="" type="checkbox"/> NOT HYPOALLERGENIC	<input checked="" type="checkbox"/> NOT HYPOALLERGENIC

1. <https://www.seas.upenn.edu/~cis535/Fall2004/HW/GCB535HW6b.pdf>. July 3, 2018. 2. American Academy of Pediatrics Committee on Nutrition. Pediatrics. 2000;106:346-9. 3. Lowe, et al. Expert Rev Clin Immunol. 2013;9:31-41. 4. Hongsprabhas, et al. Joint ACS AGFD-ACS ICST Symposium; 2014.

There are a wide range of symptoms for IgE and non-IgE mediated CMA making formula selection difficult

IgE-Mediated ¹	Non-IgE-Mediated ¹
<ul style="list-style-type: none">• Systemic IgE-mediated reactions (anaphylaxis)• IgE-mediated gastrointestinal reactions• Oral allergy syndrome• IgE-mediated respiratory reactions:<ul style="list-style-type: none">○ Asthma and rhinitis secondary to ingestion of milk○ Asthma and rhinitis secondary to inhalation of milk• IgE-mediated cutaneous reactions:<ul style="list-style-type: none">○ Acute urticaria or angioedema○ Contact urticaria• Atopic dermatitis	<ul style="list-style-type: none">• Atopic dermatitis• Gastroesophageal reflux disease (GERD)• Eosinophilic esophagitis (EoE)• Cow's milk protein-induced enteropathy• Constipation• Severe irritability (colic)• Food protein-induced gastroenteritis• Food protein-induced enterocolitis syndrome (FPIES)• Food protein-induced proctocolitis• Non-IgE-mediated respiratory reactions• Heiner's Syndrome

Quality of life may impact choice

- CMA symptoms + delayed diagnosis may affect family quality of life¹
 - Food allergies impose significant burden on parents²
 - Delayed diagnosis: ~10 wks & 4 doctor visits in UK²
 - Parents want best / fast symptom resolution

Ideal: Identify children with CMA early to prevent delay in diagnosis and choose appropriate hypoallergenic formula if breast milk is not available³

Factors may impact formula choice

Characteristic	Relevance
Nutrient profile	<ul style="list-style-type: none"> To help patients meet individualized macro- and micronutrient needs
Synbiotic (probiotic + oligosaccharides)	<ul style="list-style-type: none"> Helps balance gut microbiota dysbiosis seen in food allergy^{1,2}
Probiotic - live beneficial bacteria	<ul style="list-style-type: none"> Specific strains may help reduce future allergic manifestations / “march”^{3,4} Specific strains may help balance gut microbiota^{1,2,5}
Nucleotides	<ul style="list-style-type: none"> May improve early growth of formula-fed, SGA infants^{6,7}
No soy oil	<ul style="list-style-type: none"> Can help reduce unnecessary concern/confusion for families
No corn carbohydrate	<ul style="list-style-type: none"> Can help reduce unnecessary concern/confusion for families
Kosher pareve	<ul style="list-style-type: none"> For families who follow kosher dietary practices
Halal	<ul style="list-style-type: none"> For families who follow halal dietary practices
Pediatric formulas	<ul style="list-style-type: none"> Often indicated for food allergies beyond infancy^{8,9}
<ul style="list-style-type: none"> Flavors, pediatric 	<ul style="list-style-type: none"> Reduce flavor fatigue, support adherence
<ul style="list-style-type: none"> Liquids, pediatric 	<ul style="list-style-type: none"> Safety, convenience, adherence, social normalcy, tube feeds

1. Candy, et al. *Pediatr Res.* 2018;83:677-86. 2. Fox, et al. *Clin Transl Allergy.* 2019;9:5. 3. Berni Canani, et al. *J Allergy Clin Immunol.* 2012;129:580-2, 2.e1-5. 4. Berni Canani, et al. *J Allergy Clin Immunol.* 2017;139:1906-13.e4. 5. Hol, et al. *J Allergy Clin Immunol.* 2008;121:1448-54. 6. Singhal, et al. *Pediatrics.* 2010;126:e946-53. 7. Cosgrove, et al. *Arch Dis Child Fetal Neonatal Ed.* 1996;74:F122-5. 8. Fiocchi, et al. *Pediatr Allergy Immunol.* 2010;21 Suppl 21:1-125. 9. Groetch, et al. *J Allergy Clin Immunol Pract.* 2017;5:312-24.e29.

Evidence may impact choice

- **Growth**

- All infant formulas in US must have been demonstrated to support growth¹
- Limited data suggest height growth velocity may improve on AAF in children with food allergies who fail to fully improve on eHF²⁻⁴

- **Available research**

To summarize influential factors:

1. Important to recognize CMA early and choose the appropriate hypoallergenic formula for fast symptom management
2. For the majority of children an eHF will be a suitable substitute formula, but in a subset of children with the more severe form of CMA an AAF will be required
3. Important to consider nutritional factors from substitute formulas to make the most appropriate choice for the individual patient
4. Hypoallergenic formula choice is best informed through well-designed clinical studies

What do guidelines advise on first choice of hypoallergenic formula to manage food allergies in infants?

High-level summary: inconsistency among guidelines can lead to confusion

	CMA	Breast-fed	Anaphyl-axis	Urticaria	Procto-colitis	MFA	AD	FG/FTT	GER	EoE	FPIES
NIAID US ²	NS	Either	NS	NS	NS	NS	NS	NS	NS	NS	Either
DRACMA _{3,4}	EHF*	NS	AAF	EHF*	EHF*	NS	EHF*	NS	EHF*	AAF	AAF
ESPGHAN European _{5,6}	EHF*	Either	AAF	EHF	EHF*	AAF	NS	EHF*	EHF*	AAF	EHF*
BSACI British ⁷	EHF*	AAF	AAF	EHF	EHF*	AAF	EHF*	AAF	EHF*	AAF	AAF
with exceptions for which AAF may be recommended first	GER: NASPGHAN & ESPGHAN⁸ EoE: AAAAI⁹ FPIES: International Guidelines¹⁰								EHF	AAF	Either

1. Meyer, et al. J Allergy Clin Immunol Pract. 2018;6:383-99. 2. Boyce, et al. Nutr Res. 2011;31:61-75. 3. Fiocchi, et al. Pediatr Allergy Immunol. 2010;21 Suppl 21:1-125. 4. Motala, et al. http://www.worldallergy.org/professional/allergic_diseases_center/cows_milk_allergy_in_children/ [June 28, 2017]. 5. Koletzko, et al. J Pediatr Gastroenterol Nutr. 2012;55:221-9. 6. Papadopoulou, et al. J Pediatr Gastroenterol Nutr. 2014;58:107-18. 7. Luyt, et al. Clin Exp Allergy. 2014;44. 8. Rosen, et al. J Pediatr Gastroenterol Nutr. 2018;66:516-54. 9. Groetch, et al. J Allergy Clin Immunol Pract. 2017;5:312-24.e29. 10. Nowak-Węgrzyn, et al. J Allergy Clin Immunol. 2017.

What are practical indicators – in guidelines and literature – for use of AAFs to manage CMA?

- **Note:** Patients with food allergies may present with a combination of these indicators

Recommended
reading:

Meyer R, Groetch M, Venter C.
**When Should Infants with Cow's Milk Protein Allergy
Use an Amino Acid Formula? A Practical Guide.**

J Allergy Clin Immunol Pract. 2018;6:383-99.


When symptoms persist on an eHF¹⁻⁵

Rationale & substantiation:

- Intolerance to eHF can occur:

- Up to 10% of infants with mild CMA^{4,6}
- Up to 30% of infants with non-IgE-mediated CMA⁷
- Trend toward higher eHF “failure” with non-IgE-mediated CMA¹

- International guidelines recommend if symptoms don't completely resolve within ~2-4 weeks on an eHF, trial an AAF^{4,8}



When symptoms persist on an eHF¹⁻⁵

First choices for CMA and related conditions when formula is needed¹

Presentation or condition	NIAID US guidelines ⁶	DRACMA international guidelines ^{2,3}	ESPGHAN European guidelines ⁴	BSACI British guideline ⁵
Cow milk protein-induced enteropathy	Not specified	EHF or AAF AAF “ <i>equally reasonable</i> ” when AAF cost is low	EHF or AAF if faltering growth + “ <i>severe enteropathy</i> ”	EHF severe: AAF


1. Meyer, et al. J Allergy Clin Immunol Pract. 2018;6:383-99. 2. Luyt, et al. Clin Exp Allergy. 2014;44. 3. Fiocchi, et al. Pediatr Allergy Immunol. 2010;21 Suppl 21:1-125. 4. Motala, et al. http://www.worldallergy.org/professional/allergic_diseases_center/cows_milk_allergy_in_children/ [June 28, 2017]. 5. Koletzko, et al. J Pediatr Gastroenterol Nutr. 2012;55:221-9. 6. Boyce, et al. Nutr Res. 2011;31:61-75.

Growth faltering / Failure to thrive^{1,2}

Rationale & substantiation:

- Isolauri et al¹:
 - Similar energy intake, but length increase was higher ($p=0.006$) in the AAF group
- Niggeman et al²:
 - Similar energy intake, but significantly better height growth in children on the AAF

Length of infants with atopic dermatitis and cow milk allergy in those fed eHF versus AAF



Adapted from Isolauri et al 1995¹

Growth faltering / Failure to thrive¹⁻⁵

First choices for CMA and related conditions when formula is needed¹

Presentation or condition	NIAID US guidelines ⁶	DRACMA international guidelines ^{7,8}	ESPGHAN European guidelines ²	BSACI British guideline ³	Additional international guidelines ^{4,5}
Growth faltering / Failure to thrive	Not specified	Not specified	EHF AAF if accompanying <i>“severe enteropathy”</i>	AAF	AAF ⁵ <i>“particularly... with”</i> severe GI &/or skin presentations ⁴

1. Meyer, et al. J Allergy Clin Immunol Pract. 2018;6:383-99. **2.** Koletzko, et al. J Pediatr Gastroenterol Nutr. 2012;55:221-9. **3.** Luyt, et al. Clin Exp Allergy. 2014;44. **4.** Venter, et al. Clin Transl Allergy. 2013;3:23. **5.** Ludman, et al. BMJ. 2013;347:f5424. **6.** Boyce, et al. Nutr Res. 2011;31:61-75. **7.** Fiocchi, et al. Pediatr Allergy Immunol. 2010;21 Suppl 21:1-125. **8.** Motala, et al.

http://www.worldallergy.org/professional/allergic_diseases_center/cows_milk_allergy_in_children/ [June 28, 2017].

Studies investigating growth of infants and children with food allergies on AAF¹


First author	Type of Study	Patient Characteristics	Outcome on Growth
Niggemann et al ²	Randomized eHF vs. AAF	CMA + eczema as 1° symptom Infants	Height-for-age was significantly higher (p = 0.04) in infants on AAF
Hill et al ³	Prospective All put on AAF	Suspected non-IgE CMA Infants + children	All infants with growth failure at baseline (4/18) achieved normal growth with AAF
Sicherer et al ⁴	Non-randomized All put on AAF	IgE CMA Infants + children	No significant effect on growth at 4-mo visit (18/31), 8/31 had previously been on eHF
Borschel et al ⁵	Non-randomized All on AAF	Chronic diarrhea + allergic and/or digestive disorder Infants + children	Significant increases in weight-for-age and height-for-age in all children. Greater impact on growth in younger subjects.
Isolauri et al ⁶	Randomized eHF vs. AAF	CMA + eczema Infants	Significant increases in weight- (p= 0.09) & length-for-age (p=0.006) in AAF group vs. eHF group
McLeish et al ⁷	Randomized eHF vs. AAF	Suspected non-IgE CMA + persistent diarrhea Infants + children	Both groups were undernourished at beginning of the study, but at 24 months there were no statistical differences in growth between the 2 groups.
Vanderhoof et al ⁸	Prospective All on AAF	CMA + failed eHF + weight loss Children	Significant increase in weight (+0.433 z-score) at wk 12. Length increased over this period (NS).
Berni Canani et al ⁹	Randomized eHF vs. AAF (+HC)	CMA Infants + children	No differences in length, weight, head circumference between three groups after 12 months

1. Meyer, et al. J Allergy Clin Immunol Pract. 2018;6:383-99. 2. Niggemann, et al. Pediatr Allergy Immunol. 2001;12:78-82. 3. Hill, et al. J Allergy Clin Immunol. 1995;96:386-94. 4. Sicherer, et al. J Pediatr. 2001;138:688-93. 5. Borschel, et al. BMC Pediatr. 2014;14:136. 6. Isolauri, et al. J Pediatr. 1995;127:550-7. 7. McLeish, et al. Arch Dis Child. 1995;73:211-5. 8. Vanderhoof, et al. J Pediatr Gastroenterol Nutr. 2016;63:531-3. 9. Berni Canani, et al. J Pediatr Gastroenterol Nutr. 2017;64:632-8.

Symptoms while breastfeeding¹⁻⁴

Rationale and substantiation:

- Host et al. 1988:¹
 - Only 1 prospective study
 - 0.5% presented while on breast milk only (out of 2.2%)
- Some infants with CMA can react to residual β -lactoglobulin transferring to breast milk²
 - Breast milk: 0.9-150ug/l (median 4.2ug/l)^{3,4}
 - EHF: 0.84 -14.5ug/l^{3,4}
- However limited evidence available to substantiate this as first line formula if breast milk not available⁵



Breast milk is the preferred nutrition for infants with CMA⁵ - Infant should continue taking breast milk while, if advised, mom avoids dairy under medical supervision⁶⁻⁸

Symptoms while breastfeeding¹⁻⁶

First choices for CMA and related conditions when formula is needed¹

Presentation or condition	NIAID US guidelines ²	DRACMA international guidelines ⁷	ESPGHAN European guidelines ³	BSACI guidelines ⁴
Breast-feeding with ongoing symptoms (already on maternal elimination diet) or requiring formula, e.g. to supplement	EHF or AAF <i>“Prior to initiating an oral food challenge... until the allergic [sic] food is identified”</i>	Not specified	EHF or AAF <i>“In breast-fed infants with severe symptoms ...it is common practice in many countries to use AAF for diagnostic elimination...”</i>	AAF if symptoms when exclusively breastfed

- Limited data suggest an AAF can be used first line if formula is needed to supplement or replace breast milk because intolerance to eHF may occur^{3,5,6,8}



Carina Venter, PhD, RD

**Assistant Professor of Pediatrics,
Section of Allergy & Immunology**


**University of Colorado Denver School
of Medicine | Children's Hospital
Colorado**



Anaphylaxis¹⁻⁵

Rationale and substantiation:

- Frequency of potentially life-threatening anaphylaxis in patients with CMA varies from 0.8% to 9%²
- Case reports of anaphylactic reactions to eHFs exist^{6,7}



Anaphylaxis¹⁻⁵

First choices for CMA and related conditions when formula is needed¹

Presentation or condition	NIAID US guidelines ⁶	DRACMA international guidelines ^{2,3}	ESPGHAN European guidelines ⁴	BSACI British guideline ⁵
Anaphylaxis	Not specified	AAF	AAF	AAF


- International consensus guidelines recommend AAF first for anaphylaxis to cow milk^{2,3}
 - Hospital-based challenge to eHF can be considered if feasible¹

Eosinophilic esophagitis (EoE)¹⁻⁶

Rationale and substantiation:

- Cow milk is the main food implicated in triggering EoE^{7,8}
- 90-98% of EoE patients achieved histologic remission and symptom resolution using AAF^{1,9}

EoE: “a chronic, local immune-mediated esophageal disease, characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation.”¹⁰



Eosinophilic esophagitis (EoE)¹⁻⁶

First choices for CMA and related conditions when formula is needed¹

Presentation or condition	NIAID US guidelines ⁷	DRACMA international guidelines ^{2,3}	ESPGHAN European guidelines ⁴	BSACI British guideline ⁵	AAAAI US guidelines ⁶
Eosinophilic Esophagitis (EoE)	Not specified - evidence for AAF reviewed	AAF	AAF	AAF	AAF

□ US & international guidelines recommend AAF first-line²⁻⁶

Studies using AAF for management of EoE¹


First author	Subjects on AAF, no. and ages	Remission / Response		Notes
Kelly et al ²	10 with GERD Median 34.3 mo	80% total symptom resolution 20% partial resolution	8 / 10 2 / 10	Median counts of eosinophils/high-powered field (eos/hpf) decreased significantly from 41 (15-100) to 0.5 (0-22) (p = 0.005) after AAF trial
Liacouras et al ³	164 Median 8.1 ± 4.3 y	97.6%	160 / 164	Of 160 who improved, eosinophil counts improved from 38 ± 10.3 eos/hpf pre-diet to 1.1 ± 0.5 eos/hpf post-diet
Kagalwalla et al ⁴	25 Mean 6.4 y	88% (≤10 eos/hpf)	22 / 25	Pre-diet peak of 58.8 ± 31.9 eos/hpf decreased to post-diet peak of 3.7 ± 6.5 eos/hpf (p < 0.001)
Spergel et al ⁵	151	>95% (<15 eos/hpf)	>143 / 151	Response based on maximal eosinophil count in most severely affected esophageal biopsy specimen
Rizo Pascual et al ⁶	3	100%	3 / 3	Remission defined as <10 eos/hpf
Henderson et al ⁷	49 Median 5.6 y	96% (<15 eos/hpf)	47 / 49	Median eosinophil counts decreased from 51 (28-90) eos/hpf pre-diet to 1 (0-3.5) eos/hpf post-diet
Markowitz et al ⁸	51 Median 8.3 ± 3.1 y	96%	49 / 51	Median eosinophil counts decreased from 33.7 eos/hpf pre-diet to 1.0 eos/hpf post-diet (p < 0.01)

“Severe” or “complex” GI symptoms¹⁻⁷

➤ No definition of what “severe” or “complex” is

Rationale and substantiation:

- Children with non-IgE-mediated allergy with GI symptoms seem more likely to react to eHFs^{1,8} - though limited data
- In vitro studies suggest certain AAFs do not elicit pro-inflammatory immune responses^{9,10}



“Severe” or “complex” GI symptoms¹⁻⁷

First choices for CMA and related conditions when formula is needed¹

Presentation or condition	NIAID US guidelines ⁸	DRACMA international guidelines ^{2,3}	ESPGHAN European guidelines ⁴	BSACI British guideline ⁵	NASPGHAN & ESPGHAN ⁶
Gastroesophageal reflux	Not specified	EHF or AAF “equally reasonable” when AAF cost is low	EHF or AAF if “severe enteropathy” + faltering growth	EHF or AAF in “severe... enteropathies”	EHF or AAF if “severe symptoms”
Enteropathy					International guidelines ^{7,9}
Proctocolitis / Blood in stool					EHF or AAF if unresponsive to management

Food protein-induced enterocolitis syndrome (FPIES)¹⁻⁶

Rationale and substantiation:

- FPIES involves GI symptoms that can be severe and lead to hypotensive shock³
- Cow milk and soy are the most common FPIES triggers in the US with co-reactivity of up to ~40%³
- No clear data on best formula to use first for FPIES¹
 - Some children with FPIES exclusively tolerate AAFs³



FPIES: “a non-IgE cell-mediated food allergy”
with low awareness³

Food protein-induced enterocolitis syndrome (FPIES)¹⁻⁶

First choices for CMA and related conditions when formula is needed¹

Presentation or condition	NIAID US guidelines ²	International FPIES guidelines ³	ESPGHAN European guidelines ⁴	BSACI British guideline ⁵	DRACMA international guidelines ⁶
Food protein-induced enterocolitis syndrome (FPIES)	EHF or AAF	EHF or AAF	EHF or AAF if “severe enteropathy” + faltering growth	AAF	AAF

Multiple food allergies (MFA)¹⁻⁴

Rationale and substantiation:

- Approximately 1 in 3 children with CMA may develop allergies to other foods^{2,5} - MFA
- Children with MFA tend to have more severe food allergies¹
- Risk of poor growth increases as more allergenic foods are avoided⁶⁻⁸
 - Limited data: height growth velocity may improve on AAF in children who fail to fully improve on eHF^{5,9,10}



Multiple food allergies (MFA)¹⁻⁴

First choices for CMA and related conditions when formula is needed¹

Presentation or condition	NIAID US guidelines ⁵	DRACMA international guidelines ⁶	ESPGHAN European guidelines ²	BSACI British guideline ³
Multiple food allergies	Not specified	Not specified	AAF	AAF

- Limited data: Infants with MFA may be at higher risk of reacting to eHF^{2,4,7}

Studies using AAF for management of multiple food allergies¹

First author	Type of Study	Patient Characteristics	Number of foods eliminated
Hill et al ²	Prospective	Children with suspected delayed CMPA that stabilized on AAF	All children were referred with delayed reactions but 7/18 had positive SPT/specific IgE to a combination of milk, egg, and nuts (although many had not been exposed). Adverse delayed reactions were reported: rice, wheat and chicken.
Isolaure et al ³	Randomized, controlled	Eczema and CMPA	No intake of wheat, barley, rye, oats for 68% in the eHF group and 65% in the AAF group, as well as restrictions on various fruits and vegetables in 31% of children in the eHF group and 26% in the AAF group.
Sicherer et al ⁴	Prospective, non-randomized study	Blinded oral food challenge to AAF	29/31 children in this study had > 1 food allergy. 14/31 had ≥3 food allergies all tolerated an AAF.
Sampson et al ⁵	Prospective, DBPCFC to cow's milk, AAF and EHF.	IgE mediated CMPA	Multiple food allergies From this cohort 2 reacted to an eHF

Severe atopic dermatitis (AD)¹⁻⁵

Rationale and substantiation:

- Association exists between infant eczema and food allergy^{5,6}
 - Up to 90% of patients with CMA develop skin symptoms²
- Some data imply that combined skin and gut symptoms may require more attention in choice of hypoallergenic formula¹
- A subgroup of infants with AD may need AAF^{5,7}



Studies comparing eHF to AAF in atopic dermatitis¹

First author	Type of study	Number of subjects	Patient characteristics	Outcomes on AD
Niggemann et al ²	Randomized	31 eHF 42 AAF	Median age 5.7 mo Confirmed CMA, mixed IgE and non-IgE	No statistical difference in SCORAD (SCORing Atopic Dermatitis) between groups either 3 or 6 mo after starting formula
Isolauro et al ³	Randomized	22 eHF 23 AAF	Median age 6 mo Confirmed CMA, mixed IgE and non-IgE	No statistical difference in SCORAD at baseline or in improvements between groups
Kaczmarks et al ⁴	Prospective	67 eHF (45 eHF) (22 eHF → AAF)	Mean age 11.34 ± 8.52 mo Confirmed CMA, non-specified	22 of 67 patients had intolerance reactions to eHF 21/22 improved on AAF No significant differences in SCORAD among any groups
Leung et al ⁵	Randomized crossover	15	Median age 1.4 y 5/15 SPT + to CM 10/15 SPT + to egg and/or soy	Consumed CM or soy formula during active phase, AAF during placebo phase. Median changes for SCORAD and symptoms not significantly different between phases.

Severe atopic dermatitis (AD)¹⁻⁵


First choices for CMA and related conditions when formula is needed¹

Presentation or condition	NIAID US guidelines ⁶	DRACMA guidelines ^{2,3}	ESPGHAN European guidelines ⁷	BSACI ⁴
Atopic eczema/ atopic dermatitis (AD)	Not specified	EHF or AAF “equally reasonable” when AAF cost is low	Not specified AAF: “In breast-fed infants with severe symptoms...it is common practice...to use AAF...in these extremely sick exclusively breast-fed infants.” OR “If multiple food allergies are suspected in highly atopic children...AAF may be considered to allow symptom improvement...”	EHF or AAF in “severe” presentations ^{4,5} “particularly in association with faltering growth” ⁵


How accessible are amino acid-based formulas?

AAF may be as accessible as eHF

1. AAF coverage in 22 states



Coverage for
46% of children



Varies by insurer
54% of children

“Coverage” = Mandate or insurance agreement to cover AAFs for certain conditions and ages. Self-funded insurance plans are exempt.

AAF may be as accessible as eHF

2. **AAF pharmacy & store access increasing**
3. **AAF are WIC* eligible**
4. **Coverage & cost assistance**
programs offered by some AAF
manufacturers
5. **Online costs vary** - costs of eHFs¹ and AAFs²
are sometimes comparable



Thank you!

Nutricia North America would like to thank **Marion Groetch, MS, RD, CDN**, Senior Dietitian at Jaffe Food Allergy Institute, Mount Sinai School of Medicine, New York, NY for her expertise in the development of this presentation.

Nutricia Learning Center
is provided by
Nutricia North America

CEU/CPE Instructions

To receive your CEU/CPE certificate:

- 1) Complete the webinar survey at: <https://www.surveymonkey.com/r/cowmilkallergy>
- 2) Once webinar code is obtained, visit www.NutriciaLearningCenter.com and click on 'CE Credit Request'
- 3) Enter the webinar code obtained
- 4) Certificate will be visible for download on your NLC dashboard

